Drug Profile
Research programme: next-generation anthrax vaccines - Emergent BioSolutions
Alternative Names: dmPA 7909Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Emergent BioSolutions
- Class Anthrax vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anthrax
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anthrax in USA (Parenteral)
- 05 Oct 2009 Preclinical trials in Anthrax in USA (Parenteral)